Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD20/CD37 monoclonal antibody combination PSB202

A combination agent composed of two humanized monoclonal antibodies, PSB102, an Fc-enhanced immunoglobulin G1 (IgG1) monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen (TAA) CD20, and PSB107, an IgG1 monoclonal antibody directed against the TAA CD37, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20/CD37 monoclonal antibody combination PSB202 specifically targets and binds to CD20 and CD37 expressed on tumor cells. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CD20- and CD37-expressing B cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. CD37, a member of the tetraspanin superfamily of cell surface antigens, is overexpressed on a variety of cancer cell types and plays a key role in tumor cell proliferation.
Synonym:anti-CD20 monoclonal antibody/anti-CD37 monoclonal antibody combination PSB202
anti-CD20/anti-CD37 monoclonal antibody combination PSB202
PSB102 and PSB107
PSB102 plus PSB107
PSB102/PSB107
Code name:PSB 202
PSB-202
PSB202
Search NCI's Drug Dictionary